Rabenda V - Search Results

1

Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence.

Hiligsmann M, Gathon HJ, Bruyère O, Ethgen O, Rabenda V, Reginster JY. Hiligsmann M, et al. Among authors: rabenda v. Value Health. 2010 Jun-Jul;13(4):394-401. doi: 10.1111/j.1524-4733.2009.00687.x. Epub 2010 Jan 21. Value Health. 2010. PMID: 20102558 Free article.

2

Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.

Rabenda V, Hiligsmann M, Reginster JY. Rabenda V, et al. Expert Opin Pharmacother. 2009 Oct;10(14):2303-15. doi: 10.1517/14656560903140533. Expert Opin Pharmacother. 2009. PMID: 19640210 Review.

3

Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications.

Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY. Hiligsmann M, et al. Among authors: rabenda v. Calcif Tissue Int. 2010 Mar;86(3):202-210. doi: 10.1007/s00223-009-9329-4. Epub 2010 Jan 10. Calcif Tissue Int. 2010. PMID: 20063188

4

The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients.

Hiligsmann M, Rabenda V, Bruyère O, Reginster JY. Hiligsmann M, et al. Among authors: rabenda v. Health Policy. 2010 Jul;96(2):170-7. doi: 10.1016/j.healthpol.2010.01.014. Epub 2010 Feb 13. Health Policy. 2010. PMID: 20153543

5

Potential clinical and economic impact of nonadherence with osteoporosis medications.

Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY. Hiligsmann M, et al. Among authors: rabenda v. Calcif Tissue Int. 2010 Mar;86(3):202-10. Calcif Tissue Int. 2010. PMID: 20205345

6

Overcoming problems with adherence to osteoporosis medication.

Rabenda V, Reginster JY. Rabenda V, et al. Expert Rev Pharmacoecon Outcomes Res. 2010 Dec;10(6):677-89. doi: 10.1586/erp.10.76. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 21155701 Review.

7

The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.

Hiligsmann M, Boonen A, Rabenda V, Reginster JY. Hiligsmann M, et al. Among authors: rabenda v. Expert Rev Pharmacoecon Outcomes Res. 2012 Apr;12(2):159-66. doi: 10.1586/erp.12.8. Expert Rev Pharmacoecon Outcomes Res. 2012. PMID: 22458617 Free article. Review.

8

Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis.

Hiligsmann M, Ben Sedrine W, Bruyère O, Evers SM, Rabenda V, Reginster JY. Hiligsmann M, et al. Among authors: rabenda v. Eur J Public Health. 2015 Feb;25(1):20-5. doi: 10.1093/eurpub/cku119. Epub 2014 Aug 5. Eur J Public Health. 2015. PMID: 25096255

9

[Adherence to treatment in osteoporosis influence on efficiency].

Reginster JY, Rabenda V. Reginster JY, et al. Among authors: rabenda v. Rev Med Suisse. 2005 Oct 5;1(35):2278-81. Rev Med Suisse. 2005. PMID: 16268451 French.

10

[Prevention and treatment of osteoporosis: avoiding clinical inertia and promoting therapeutic adherence].

Rabenda V, Reginster JY. Rabenda V, et al. Rev Med Liege. 2010 May-Jun;65(5-6):358-65. Rev Med Liege. 2010. PMID: 20684420 Free article. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters